The mixed analyst ratings indicate uncertainty in the market's perception of Celldex Therapeutics. The slight increase in the average price target suggests a modest positive outlook. However, the company's profitability challenges and below-average asset returns may offset the positive revenue growth, leading to a neutral short-term impact on the stock price.